Safety of brigatinib following alectinib-induced-pneumonitis: Case report

IF 0.8 Q4 RESPIRATORY SYSTEM Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI:10.1016/j.rmcr.2024.102160

Blerina Resuli , Heidi Galarza , Laura Elsner , Diego Kauffmann-Guerrero , Jürgen Behr , Amanda Tufman

{"title":"Safety of brigatinib following alectinib-induced-pneumonitis: Case report","authors":"Blerina Resuli , Heidi Galarza , Laura Elsner , Diego Kauffmann-Guerrero , Jürgen Behr , Amanda Tufman","doi":"10.1016/j.rmcr.2024.102160","DOIUrl":null,"url":null,"abstract":"<div><div>Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.</div><div>We report a case of a patient with ALK positive advanced NSCLC who developed pneumonitis during treatment with first-line alectinib. With no alternative etiology of pneumonitis identified, the patient was treated with corticosteroids and discontinuation of alectinib. Following rapid clinical recovery and radiographic resolution of the opacities, the patient was started with brigatinib, with no recurrence of the clinical symptoms or radiographic findings of pneumonitis. While further descriptions are needed, our experience suggests that switching to a second ALK-TKI may be a safe therapeutic option in some patients who develop drug-induced pneumonitis on ALK TKIs.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"53 ","pages":"Article 102160"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743586/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007124001837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.

We report a case of a patient with ALK positive advanced NSCLC who developed pneumonitis during treatment with first-line alectinib. With no alternative etiology of pneumonitis identified, the patient was treated with corticosteroids and discontinuation of alectinib. Following rapid clinical recovery and radiographic resolution of the opacities, the patient was started with brigatinib, with no recurrence of the clinical symptoms or radiographic findings of pneumonitis. While further descriptions are needed, our experience suggests that switching to a second ALK-TKI may be a safe therapeutic option in some patients who develop drug-induced pneumonitis on ALK TKIs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿勒替尼致肺炎后布加替尼的安全性：病例报告

间变性淋巴瘤激酶酪氨酸激酶抑制剂（ALK TKIs）显示出强大的疗效，并彻底改变了ALK重排的非小细胞肺癌患者的治疗。ALK TKIs可产生副作用，有时甚至严重，如肺炎。我们报告一例ALK阳性晚期非小细胞肺癌患者在一线阿勒替尼治疗期间发生肺炎。由于没有确定肺炎的其他病因，患者接受皮质类固醇治疗并停用阿勒替尼。在快速的临床恢复和影像学检查后，患者开始使用布加替尼，没有复发的临床症状或肺炎的影像学表现。虽然需要进一步的描述，但我们的经验表明，对于一些服用ALK- tki后出现药物性肺炎的患者，改用第二种ALK- tki可能是一种安全的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊